Leerink Partners analyst David Risinger has maintained their bullish stance on JNJ stock, giving a Buy rating on May 1.
David Risinger has given his Buy rating due to a combination of factors related to Johnson & Johnson’s promising developments in their TAR-200 platform for bladder cancer treatment. The company has reported strong data from their SunRISe-1 Cohort 4 study, which showed an impressive 9-month disease-free survival rate of 81.1% in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC) with papillary disease. This result suggests a significant potential for TAR-200 to become a preferred treatment option, potentially replacing more invasive procedures like radical cystectomy.
Moreover, the safety profile of TAR-200 was favorable, with most adverse events being mild and manageable. The large market opportunity, given that a substantial portion of bladder cancer patients fall into the non-muscle invasive category, further supports the positive outlook. Johnson & Johnson’s management projects peak sales exceeding $5 billion for the TARIS platform, indicating strong future revenue potential. These factors combined with the company’s strategic plans for regulatory approval in 2026, underpin Risinger’s optimistic Buy rating for JNJ stock.
In another report released on May 1, RBC Capital also maintained a Buy rating on the stock with a $181.00 price target.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JNJ in relation to earlier this year.